Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Hanmi Genentech obesity drug deal worth $2.3B reported — Aug 24, 2026Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.